Pearce IP BioBlast™: w/e 10 July 2020

by , | Jul 13, 2020

Significant biosimilar activities this week include

05 Jul 20 | In its 2019-2020 Annual Report, Biocon announced it plans to list Biocon Biologics on Indian markets within the next two to three years, depending on market conditions.

07 Jul 20 | Outlook Therapeutics announced it has completed patient enrollment for its NORSE 2 clinical trials of Lytenava® (proposed bevacizumab biosimilar).

08 Jul | US | Genentech and Amgen filed stipulations in the US District Court of Delaware dismissing their BPCIA litigation relating to trastuzumab and bevacizumab biosimilars.  This comes after the Court of Appeals refused to block Amgen’s Mvasi® from entering US markets on July 06.

08 Jul | The Journal of Clinical Pathways reported a new study shows a triplet regimen of pembrolizumab, Herzuma® (trastuzumab) and chemotherapy is effective in patients with HER-2 positive advanced gastric cancer.

09 Jul | US | Mylan announced FDA approval of Hulio® (biosimilar adalimumab) for PFS and auto-injector presentations.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News